Skip to main content
Advanced Search
Search Terms
Content Type

Exact Matches
Tag Searches
Date Options
Updated after
Updated before
Created after
Created before

Search Results

4 total results found

User Manual for Materials Consumption Simulator

Material Consumption Simulator User Manual

中文版 物料消耗模拟器用户指南 Materials Consumption Simulator Materials Consumption Simulator 1. Why Simulate 1.1. The Base Scenario C0 Imagine you are the Project Manager (PM) overseeing a single-center randomized controlled trial (RCT). The trial design is pre...

Type
Manual
Status
Draft
Date
2025-12

A Review of Clinical Pharmacology Considerations in Antibody-drug Conjugates Approved by the US Food and Drug Administration Between 2000 and 2025

Fun Fact ADC

by Seoyoung Koo, Chae Yeon Kim, Jeong-hyeon Lim, Eunyoung Lee, In Young Kim, Young G. Shin, and Hanlim Moon Abstract Antibody-drug conjugates (ADCs) represent a promising class of anticancer therapies with rapidly expanding development. However, regulatory app...

Type
Article
Status
Final
Date
2025-12

单臂临床试验用于支持抗肿瘤药物常规上市申请技术指导原则

General NMPA

一、概述 单臂临床试验(single arm trial,SAT)是不设立平行对照,采用开放设计,不涉及随机与盲法的一种临床试验设计。 在抗肿瘤治疗领域,为了推动新药及早上市,解决患者未满足的临床急需,对于有效性结果十分突出的抗肿瘤药物,可以依据SAT的试验结果支持上市申请。与公认的金标准——随机对照试验(randomized controlled trial,RCT)结果相比,SAT缺乏平行对照,且往往以替代终点作为主要终点,以快速评估新药的初步有效性和安全性,其结果往往是与历史数据、预先设定的基准或者疾病自然进...

Type
Guideline
Status
Final
Date
2025-12

针对泛肿瘤的抗肿瘤药物临床研发技术指导原则

General NMPA

一、背景 传统的临床实践主要基于肿瘤的原发部位和病理组织学分型进行诊断、判断预后以及支持治疗决策。分子生物学和免疫学的研究进步推动了对肿瘤关键异常分子改变的发现,从而改变了医学界对肿瘤的全面认识。某些分子改变可能同时存在于不同组织来源的肿瘤细胞中,导致这些肿瘤具有类似的生物学发生发展机制。因此,业界提出了“不限组织来源的肿瘤”(Tumor-Agnostic)或“泛 肿瘤”(Pan-tumor)(以下简称“泛肿瘤”)的概念。泛肿瘤是从肿瘤起源和病因学等角度,将多种组织来源的肿瘤视为同一类疾病,并且寻求相同的治疗手段。...

Type
Guideline
Status
Final
Date
2025-12